Past, present, and future policy considerations regarding meningococcal vaccination in the United States.

Autor:	Clements DE; U.S. Medical and Clinical Affairs, Vaccines, GSK, Philadelphia, PA, USA., Olaiya T; U.S. Medical and Clinical Affairs, Vaccines, GSK, Philadelphia, PA, USA., Burman C; U.S. Medical and Clinical Affairs, Vaccines, GSK, Philadelphia, PA, USA., Herrera-Restrepo O; U.S. Medical and Clinical Affairs, Vaccines, GSK, Philadelphia, PA, USA., Sohn WY; Global Medical Affairs, GSK, Rockville, MD, USA., Folaranmi T; U.S. Medical and Clinical Affairs, Vaccines, GSK, Philadelphia, PA, USA., Abbing-Karahagopian V; Epidemiology, Value Evidence and Outcomes, GSK, Amsterdam, Netherlands., Marshall GS; Department of Pediatrics, Division of Pediatric Infectious Diseases, Norton Children's and the University of Louisville School of Medicine, Louisville, KY, USA., Conway JH; Department of Pediatrics, The University of Wisconsin-Madison School of Medicine & Public Health, Madison, WI, USA.
Jazyk:	angličtina
Zdroj:	Expert review of vaccines [Expert Rev Vaccines] 2024 Jan-Dec; Vol. 23 (1), pp. 845-861. Date of Electronic Publication: 2024 Sep 11.
DOI:	10.1080/14760584.2024.2397705
Abstrakt:	Introduction: In 2005, the United States Advisory Committee on Immunization Practices (ACIP) recommended routine vaccination against invasive meningococcal disease (IMD) caused by serogroups A, C, W, and Y (MenACWY) for all 11-12-year-olds, as well as 2-10-year-olds at high risk. In 2010, a booster dose was recommended for all 16-year-olds, as well as for high-risk patients every 3-5 years. In 2015, optional (as opposed to routine) vaccination against meningococcal serogroup B (MenB) at the preferred age of 16-18 years was recommended (Category B, later changed to shared clinical decision-making). In 2023, a vaccine (MenABCWY) against the five serogroups primarily responsible for IMD in the U.S. became available. Areas Covered: This review summarizes the evolution of public policy that led to each milestone vaccine recommendation, reviews epidemiologic data published following the recommendations, and discusses the current state of meningococcal immunization policy. Expert Opinion: The use of MenABCWY has the potential to consolidate policy, improve coverage rates for the five serogroups, address disparities in vaccination coverage, and simplify vaccine delivery.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu